PTX-200 is under clinical development by Prescient Therapeutics and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PTX-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PTX-200 overview

Triciribine phosphate monohydrate (PTX-200, TCN-P) is under development for the treatment of relapsed and refractory acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and HER-2 negative breast cancer. The drug candidate is administered intravenously. The drug candidate is the phosphate salt of the synthetic, cell-permeable tricyclic nucleoside triciribine. It is a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT). It was also under development for multiple myeloma, pancreatic cancer, , platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), agnogenic myeloid metaplasia (AMM), metastatic breast cancer and various tumors, lung cancer, oesophagal cancer.

Prescient Therapeutics overview

Prescient Therapeutics, formerly Virax, is a biotechnology company. It develops novel medicines for cancer treatment. The company is investigating OmniCAR, an immune receptor platform that controls T-cell activity and multi-antigen targeting with a single-cell product for a combined approach to formulate novel chimeric antigen receptor T (CAR-T) to treat cancer and other diseases. Its pipeline products include PTX-100, a compound that blocks geranylgeranyl transferase-1 (GGT-1), a cancer growth enzyme; and PTX-200, a novel PH domain inhibitor that obstructs protein kinase B or AKT signaling, which develops breast, ovarian cancer and leukemia. Prescient Therapeutics is headquartered in South Melbourne, Victoria, Australia.

For a complete picture of PTX-200’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.